I
Igor Vidal
Researcher at Johns Hopkins University School of Medicine
Publications - 14
Citations - 166
Igor Vidal is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 2, co-authored 8 publications receiving 92 citations.
Papers
More filters
Journal ArticleDOI
Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study
Michael A. Gorin,Steven P. Rowe,Hiten D. Patel,Igor Vidal,Margarita Mana-ay,Mehrbod S. Javadi,Lilja B. Solnes,Ashley E. Ross,Edward M. Schaeffer,Trinity J. Bivalacqua,Alan W. Partin,Kenneth J. Pienta,Zsolt Szabo,Angelo M. De Marzo,Martin G. Pomper,Mohamad E. Allaf +15 more
TL;DR: The results support the need for a larger study to more precisely define the diagnostic accuracy of this novel molecular imaging test and allow for accurate detection of prostate cancer sites in men believed to have clinically localized disease based on conventional imaging.
Journal ArticleDOI
Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.
Jelani C. Zarif,Jelani C. Zarif,Javier Valle,Jessica L. Hicks,Christopher M. Heaphy,Christopher M. Heaphy,Igor Vidal,Jacob Luo,Tamara L. Lotan,Jody E. Hooper,William B. Isaacs,William B. Isaacs,Kenneth J. Pienta,Kenneth J. Pienta,Angelo M. De Marzo,Angelo M. De Marzo +15 more
TL;DR: The results provide a rationale for therapeutic targeting of macrophages in the PC microenvironment as a potential method to augment immunotherapeutic responses and help explain the lack of clinical success of immunotherapy for PC patients.
Journal ArticleDOI
GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasms
Daniela C. Salles,Kaushal Asrani,Ju Hyung Woo,Thiago Vidotto,Hans B. Liu,Igor Vidal,Andres Matoso,George J. Netto,Pedram Argani,Tamara L. Lotan +9 more
TL;DR: The immunophenotype of tRCC and TSC1/2/MTOR alteration‐associated renal tumors is highly overlapping, likely due to the increased activity of TFE3/TFEB in both, revealing an important caveat regarding the use of T FE3/ TFEB‐transcriptional targets as diagnostic markers.
Journal ArticleDOI
P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Janielle P. Maynard,Jiayun Lu,Igor Vidal,Jessica L. Hicks,Luke Mummert,Tamirat Ali,Ryan Kempski,Ayanna M Carter,Rebecca Y Sosa,Lauren B. Peiffer,Corinne E. Joshu,Tamara L. Lotan,Angelo M. De Marzo,Karen S. Sfanos +13 more
TL;DR: In this paper, the P2X4 protein expression was observed primarily in epithelial cells of the prostate, a subset of CD66+ neutrophils, and most CD68+ macrophages.
Journal ArticleDOI
GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States
Igor Vidal,Qizhi Zheng,Jessica L. Hicks,Jiayu Chen,Elizabeth A. Platz,Bruce J. Trock,Bruce J. Trock,Ibrahim Kulac,Javier Valle,Karen S. Sfanos,Sarah E. Ernst,Tracy Jones,Janielle P. Maynard,Stephanie Glavaris,William G. Nelson,Srinivasan Yegnasubramanian,Angelo M. De Marzo +16 more
TL;DR: In this article, the authors used immunohistochemistry against GSTP1 to examine 1673 primary prostatic adenocarcinomas on tissue microarrays (TMAs) with redundant sampling from the index tumor from prostatectomies.